共 50 条
- [21] Results of a phase II study of a human anti-interleukin (IL)-12/IL-23 monoclonal antibody in the treatment of psoriasisJOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (01) : A6 - A6Langley, RLebwohl, MLeonardi, CYeilding, NGuzzo, CWang, YDooley, LKrueger, GG
- [22] Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J)JOURNAL OF DERMATOLOGY, 2017, 44 (04): : 355 - 362Saeki, HidehisaNakagawa, HidemiNakajo, KoIshii, TaekoMorisaki, YojiAoki, TakehiroCameron, Gregory S.Osuntokun, Olawale O.
- [23] Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity during long-term treatment in subjects with moderate to severe plaque psoriasisJOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S15 - S15Reich, KristianBlauvelt, AndrewArmstrong, AprilFox, ToddHuang, JiaqingBruin, Gerard
- [24] Serum lipidomic study of long-chain fatty acids in psoriasis patients prior to and after anti-IL-17A monoclonal antibody treatment by quantitative GC‒MS analysis with in situ extractionLipids in Health and Disease, 23XiaoYu GuoJianglu ZhouHong YuHan CaoXia LiQing HuYunQiu Yu
- [25] Patient reported outcomes after 16 weeks treatment with subcutaneous ixekizumab in a phase 2 trial in patients with moderate to severe plaque psoriasisJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 26 - 26Zachariae, C.Edson-Heredia, E.Erickson, J. S.Cameron, G.Zhu, B.Matheson, R.
- [26] Serum lipidomic study of long-chain fatty acids in psoriasis patients prior to and after anti-IL-17A monoclonal antibody treatment by quantitative GC-MS analysis with in situ extractionLIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)Guo, XiaoyuZhou, JiangluYu, HongCao, HanLi, XiaHu, QingYu, Yunqiu
- [27] Phase II study of a human anti-interleukin (IL)-12/IL-23 monoclonal antibody in the treatment of psoriasisJOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (03) : A69 - A69Langely, RGLebwohl, MLeonardi, CYeilding, NGuzzo, CWang, YDooley, LKrueger, GG
- [28] A Phase Ib/II Randomized, Double-blind, Placebo-controlled Study of Novel anti-IL-17A Monoclonal Antibody JS']JS005 in Patients with Moderate to Severe PsoriasisARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3809 - 3811Cai, LinMu, ZhangleiTao, XiaohuaZhang, LitaoZhang, ChunleiLi, YumeiZhang, GuoqiangZhang, FurenDong, XiuqinLi, ChengxinChen, AijunWu, ZhuningZhu, YuxianZhang, MengqiLiu, JiangnianZhang, Jianzhong
- [29] MK-3222, an anti-IL-23p19 humanized monoclonal antibody, provides significant improvement in psoriasis over 52 weeks of treatment that is maintained after discontinuation of dosingJOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB176 - AB176Langley, Richard G. B.Thaci, DiamantPapp, Kim A.Reich, KristianLi, QingShames, RichardZhou, Yijie
- [30] Long-term efficacy and safety results from an open-label phase III study (UNCOVER-J) in Japanese plaque psoriasis patients: impact of treatment withdrawal and retreatment of ixekizumabJOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (03) : 568 - 576Umezawa, Y.Torisu-Itakura, H.Morisaki, Y.ElMaraghy, H.Nakajo, K.Akashi, N.Saeki, H.Akasaka, ToshihideAsano, YoshihideEtoh, TakafumiFujita, YasuyukiHashimoto, TakashiHigashiyama, MariIgarashi, AtsuyukiIhn, HironobuIwatsuki, KeijiKabashima, KenjiKawada, AkiraKawashima, MakotoNakamura, KoichiroOkubo, YukariOkuyama, RyuheiOzawa, AkiraSayama, KojiSeishima, MarikoShiohara, TetsuoTakahara, MasakazuTakahashi, HidetoshiTakehara, KazuhikoTanese, KeijiTani, MamoriUmezawa, YoshinoriWatanabe, HideakiYamanaka, Keiichi